Published in final edited form as:

Horm Cancer. 2013 February ; 4(1): 50–59. doi:10.1007/s12672-012-0125-7.

Requirement for Stromal Estrogen Receptor Alpha in Cervical Neoplasia

Sang-Hyuk Chung^{1,2}, Myeong Kyun Shin¹, Kenneth S. Korach³, and Paul F. Lambert^{1,*}

¹McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI 53706, U.S.A.

²Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, U.S.A

³Laboratory of Reproductive & Developmental Toxicology, NIEHS, Research Triangle Park, NC 27709, U.S.A.

Abstract

The major etiological factor for cervical cancer is the high-risk human papillomavirus (HPV), which encodes *E6* and *E7* oncogenes. However, HPV is not sufficient and estrogen has been proposed as an etiological cofactor for the disease. Its requirement has been demonstrated in mouse models for HPV-associated cervical cancer (*e.g.*, *K14E7* transgenic mice). Although germline knockout of estrogen receptor alpha (ER α) renders mice resistant to cervical cancer, the cell type-specific requirement for ER α is not known. In this study, we demonstrate that temporal deletion of stromal ER α induced complete regression of cervical dysplasia in *K14E7* mice. Our results strongly support the hypothesis that stromal ER α is necessary for HPV-induced cervical carcinogenesis and implicate paracrine mechanisms involving ER α signaling in the development of estrogen-dependent cervical cancers. This is the first evidence to support the importance of stromal ER α in estrogen-dependent neoplastic disease of the female reproductive tract.

Keywords

cervical cancer; HPV; stromal ER α ; transgenic mouse model

Introduction

Cervical cancer is the second most frequent cancer and the second leading cause of death by cancer in women worldwide [1, 2]. The vast majority of cervical cancer is associated with specific types of human papillomavirus (HPV), the so-called high-risk HPVs. Specifically, the high-risk HPV16 and HPV18 genotypes are found in approximately 60% and 20% of all cervical cancers, respectively [3]. The tumorigenic potential of these viruses stems mainly from two viral oncogenes, E6 and E7, which are best known for their ability to inactivate p53 and pRb tumor suppressor protein, respectively [2-4]. These oncogenes are necessary for the progression of cervical disease (CIN1, CIN2, CIN3, invasive cancer) and the continued growth of cervical cancer. It is estimated that approximately 75% of sexually active women are infected with HPVs, yet only a minor fraction of such women develops

*Corresponding author: Paul F. Lambert; Mailing address: McArdle Laboratory for Cancer Research, 1400 University Ave., Madison, WI 53706 U.S.A.; Phone: (608) 262-8533; Fax: (608) 262-2824; lambert@oncology.wisc.edu.

Conflict of Interest

The authors have no conflict of interest.

cervical cancer [5]. This observation has suggested that HPV infection alone is not sufficient for cervical cancer and that other cofactors are also necessary. Long-term use of oral contraceptives (OCs) or high parity is associated with higher risk for cervical cancer in HPV-infected women [6, 7]. These results implicate estrogen and/or progesterone in HPV-induced cervical cancer because they are the factors common to both variables (OCs and pregnancy). Complications in looking at a specific association of estrogen in human cervical cancer are discussed in a recent review [8] and the role of estrogen in human cervical cancer therefore remains unclear.

An essential role of estrogen in cervical cancer, however, has been clearly defined in HPV transgenic mouse models. HPV16 transgenic mice express the E6 (*K14E6*), E7 (*K14E7*), or both (*K14E6/K14E7*) oncogenes under the control of human keratin 14 (K14) promoter, which drives transgene expression in stratified squamous epithelia, the natural host cell type for HPV infection. An HPV oncogene in conjunction with physiologic levels of exogenous estrogen promotes the development of cervical cancer, whereas either one of the two factors alone does not [9-12]. Using this validated hormone/oncogene co-dependence mouse model, we previously determined that estrogen receptor α (ER α) is necessary for estrogen to cooperate with HPV in the development and continued growth of cervical cancer [13, 14].

Stromal cells play a pivotal role in development. For example, recombination of uterine stroma with vaginal epithelium results in the development of uterine epithelium *in vivo* [15]. More recently, an *in vivo* uterine epithelial specific ER α knockout shows estrogen-induced proliferation dependent on uterine stroma [16]. Stromal microenvironment also contributes to the development of carcinomas. For instance, cancer cell-derived TGF- β promotes transdifferentiation of fibroblasts to myofibroblasts, which in turn support and/or promote cancer cell invasion and metastasis [17]. Stromal p53 mutation is associated with nodal metastasis in sporadic breast cancers [18] and deletion of the APC tumor suppressor in the stroma promotes the development of endometrial cancer in mice [19]. Such signaling pathways in stroma that support carcinogenesis are attractive targets for cancer therapy.

ER α is crucial for the estrogenic responses (*e.g.*, epithelial cell proliferation) of hormone-responsive tissues such as mammary glands and female reproductive tracts [20]. It is also critical for various cancers including breast cancer [21]. Although a role of stromal ER α in tissue homeostasis and organogenesis has been extensively evaluated [16, 22, 23], it is poorly understood in the context of cancer. In the present study, we utilized conditional *ER α* knockout (*ER α ^{fl/fl}*) mice to assess whether stromal ER α is important for cervical carcinogenesis in the *K14E7* transgenic mouse model. Our results show for the first time that ER α expressed in stromal cells is required for estrogen-dependent cervical cancer in the HPV transgenic mouse model.

Materials and Methods

Mice and treatments

K14E7 transgenic mice and conditional *ER α* knockout (*ER α ^{fl/fl}*) mice were described previously [24, 25]. *CAGGCre-ERTM* (referred to as *CMVCreER* herein) transgenic mouse was purchased from the Jackson Laboratory [26]. This mouse was generated to drive expression of tamoxifen-inducible cre recombinase ubiquitously in all tissues and cell types. Experimental mice were generated by crossing *K14E7/ER α ^{fl/fl}* and *CMVCreER/ER α ^{fl/fl}*, which were obtained by intercrossing F1 generations of *K14E7* (FVB) and *ER α ^{fl/fl}* (albino C57BL/6) mating and *CMVCreER* (C57BL/6 $\times$ CBA $\times$ SWR) and *ER α ^{fl/fl}* mating, respectively. Female progenies were genotyped by PCR. A slow-releasing 17 β -estradiol tablet (0.05 mg/60 days) (Innovative Research of America, Sarasota, FL) was inserted subcutaneously under the dorsal skin every two months beginning at 4-6 weeks of age.

Groups of mice were injected intraperitoneally (i.p.) with tamoxifen (4 mg/day) for 5 days after 6-month estrogen treatment to activate cre [26]. Mice were injected i.p. with 0.3 ml of bromo-deoxyuridine (BrdU) (12.5 mg/ml) 1 hr prior to euthanasia to measure cellular proliferation. All procedures were carried out according to an animal protocol approved by the University of Wisconsin Medical School Institutional Animal Care and Use Committee.

Tissue processing and histological analyses

Female reproductive tracts were fixed in 4% paraformaldehyde (PFA) and embedded in paraffin. Serial sections were made throughout cervixes at 5- μ m thickness. Every tenth slide was stained with hematoxylin and eosin (H&E) and the worst disease in each mouse was determined as described previously [11].

Immunohistochemistry

Antibodies were purchased from Santa Cruz [PR (H190) and ER α (MC20)], Calbiochem (BrdU), Rockland (biotinylated anti-rabbit/mouse IgG), Invitrogen (anti-rabbit IgG conjugated with Alexa 488). Immunohistochemical stainings for PR, ER α and BrdU were performed as described previously [13, 27, 28].

Statistical analyses

Two-sided Fisher's exact test and Wilcoxon rank sum test were carried out with MSTAT software version 5.4¹. Fisher's exact test was used for cancer incidence and number of disease-free mice, and Wilcoxon rank sum test for disease severity and number of ER α ⁺ or BrdU⁺ cells.

Results

Tamoxifen treatment induces deletion of ER α in the cervical stroma but not in the epithelium of CMVCreER/ER α ^{ff} mice

The initial goal of this study was to evaluate the temporal requirements for ER α in all cells within the cervix during different stages in cervical carcinogenesis. To accomplish this we made use of the ER α ^{ff} mice carrying a conditional (floxed) allele of ER α , crossed to the CMVCreER mice which were chosen because they were expected to drive Cre expression ubiquitously in all tissues and cell types of the mouse reproductive tract and other organs. We tested various tamoxifen treatment regimens (daily i.p. injections, 0.5, 1, 2, 3, 4, 5 mg/day for 1, 3, or 5 days) based on prior studies [26, 29]. The effect of each dosing schedule was initially evaluated by monitoring for gross changes in the reproductive tracts and measuring their wet weight after 2 weeks of the first dose. We observed that treatment with 4 mg of tamoxifen for 5 days resulted in most dramatic morphological changes without morbidity (Fig. 1a). Tamoxifen-treated mice had hemorrhagic ovaries and atrophic reproductive tracts, which is reminiscent of ER α knockout mice [30]. Although treatment with 5 mg of tamoxifen for 3 days resulted in similar effects in surviving animals, this dose incurred morbidity and mortality in 2 of 5 mice (40%). We also evaluated ER α expression by immunohistochemistry (IHC). To our surprise, ER α expression was not affected in the cervical epithelium, yet absent in the cervical stroma (Fig. 1b, *top panel*). In contrast, ER α expression was abrogated in both epithelium and stroma of the uterus (Fig. 1b, *bottom panel*). We did not observe epithelial ER α deletion in cervixes of CMVCreER/ER α ^{ff} mice treated with 4 mg of tamoxifen for 1, 3, or 5 days and sacrificed 24 hours after the final injection (Online Resource 1). ER α expression was also retained in the cervical epithelium of K14Cre/ER α ^{ff} mice of which ovaries are removed (Online Resource 1), despite the fact

¹<http://www.mcardle.wisc.edu/mstat>

that *K14Cre* efficiently deletes other floxed genes in the cervical epithelia [31, 32]. This raises the possibility that the floxed ER α allele in cervical epithelial cells is resistant to cre-mediated recombination. Regardless of why the ER α allele was not deleted in the cervical epithelia, this fact provided us the opportunity to evaluate the individual role of stromal ER α in cervical carcinogenesis.

Cervical disease is absent in *CMVCreER/K14E7/ER α^{ff}* mice treated with tamoxifen for 5 days

To address whether stromal ER α is crucial for cervical carcinogenesis in the mouse model we generated *CMVCreER/K14E7/ER α^{ff}* and *K14E7/ER α^{ff}* mice, and each genotype was divided into three treatment groups (Fig. 2a). Female reproductive tracts were harvested after treatment with 17 β -estradiol (E2) for 6 months (6mE2 group), which is sufficient to promote cervical cancer in *K14E7* mice at varying penetrance depending on experimental conditions and genetic background [11, 13, 32, 33]. The other groups were further treated with E2 for 2 more months and given oil vehicle [8mE2 (-Tam) group] or tamoxifen [8mE2 (+Tam) group] for 5 days at 6-month-treatment with E2. These treatment regimens were designed to evaluate importance of stromal ER α in continued growth of cervical cancer and progression of CIN to invasive cancer. Female reproductive tracts were isolated at each end point as depicted in Fig. 2a. Each mouse was histopathologically evaluated for the worst cervical and vaginal disease as previously described (ER α -dependent vaginal cancer also arises in our mouse model)[10, 13].

The vast majority of *K14E7/ER α^{ff}* 6mE2 (14 of 14) and *CMVCreER/K14E7/ER α^{ff}* 6mE2 (12 of 14) mice had high-grade dysplasia, CIN2/3, indicative of neoplastic progression, though none had developed cervical cancer (Table 1). This was surprising because E2 treatment for 6 months is sufficient to promote cervical cancers in the majority of *K14E7* transgenic mice on FVB background [11, 32]. By 8-month E2 treatment cervical cancers were beginning to arise in both the *K14E7/ER α^{ff}* and *CMVCreER/K14E7/ER α^{ff}* mice (Table 1). Considering that mice used in this study are on a mixed genetic background from 4 strains, these data indicate that the rate of progression of cervical carcinogenesis likely depends on the genetic background of mice. The high penetrance of high-grade dysplasia at the 6-month E2 treatment endpoint did provide us the ability to ask what is the importance of stromal ER α in this stage of cervical neoplasia. That the overall disease severity ($p = 0.07$) and number of cervical disease-free mice ($p = 0.48$) were not significantly different between the *K14E7/ER α^{ff}* 6mE2 and *CMVCreER/K14E7/ER α^{ff}* 6mE2 (not treated with tamoxifen) confirmed that *CMVCreER* transgene itself had no influence on cervical carcinogenesis. As mentioned before, cervical cancers were observed when both genotypes were treated with E2 for 8 months [2 of 15 *K14E7/ER α^{ff}* 8mE2 (-Tam) mice and 1 of 4 *CMVCreER/K14E7/ER α^{ff}* 8mE2 (-Tam) mice]. Overall disease severity in *CMVCreER/K14E7/ER α^{ff}* 8mE2 (-Tam) and *K14E7/ER α^{ff}* 8mE2 (-Tam) was similar ($p = 0.29$), confirming no significant effect of *CMVCreER* transgene in the absence of tamoxifen treatment. Consistently, cervical epithelia of *K14E7/ER α^{ff}* 8mE2 (-Tam) and *CMVCreER/K14E7/ER α^{ff}* 8mE2 (-Tam) were histologically indistinguishable (Fig. 2b, panels i & ii). Next we compared cervical disease phenotypes between *K14E7/ER α^{ff}* 8mE2 (-Tam) and *K14E7/ER α^{ff}* 8mE2 (+Tam). The number of cervical disease-free mice ($p = 0.11$) and overall disease severity ($p = 0.06$) were not significantly different between these two control groups (Table 1). Their epithelia also were similar to each other at the histological level (Fig. 2b, panels i & iii). These control comparisons indicate that the 5-day-long tamoxifen treatment itself has no significant effect on cervical carcinogenesis in our mouse model. Strikingly, only 2 of 18 (11.1%) *CMVCreER/K14E7/ER α^{ff}* 8mE2 (+Tam) mice had CIN3 and the rest were disease-free, whereas 14 of 18 *K14E7/ER α^{ff}* 8mE2 (+Tam) mice had CIN3 or cervical cancer (Table 1). Differences in the overall disease severity ($p = 3.7 \times$

10^{-5}) and the frequency of disease-free mice ($p = 1.3 \times 10^{-4}$) between the two groups were highly significant. The cervical epithelia of *CMVCreER/K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice were hypoplastic compared to those of *K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice (Fig. 2b, panels *iii* & *iv*). Similar differences in disease phenotypes between these two groups were observed in vaginal tissues (Table 1).

Cervical disease states correlate with ER α status in the cervical stroma

In order to confirm that the absence of cervical disease in *CMVCreER/K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice was due to lack of ER α expression in the stroma, we evaluated cervical tissues for ER α expression by IHC. As expected, ER α expression was readily detected in stroma and epithelia of *K14E7/ERa^{fl/fl}* 8mE2 (-Tam), *K14E7/ERa^{fl/fl}* 8mE2 (+Tam), and *CMVCreER/K14E7/ERa^{fl/fl}* 8mE2 (-Tam) mice (Fig. 3a, panels *i-iii*). In contrast and similar to that shown in Fig. 1b, ER α -positive stromal cells were rarely found in *CMVCreER/K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice, while ER α expression in the epithelia remained highly penetrant (Fig. 3a, panel *iv*). Quantitative analyses showed that only 1.2% of cervical stromal cells in disease-free *CMVCreER/K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice expressed ER α , whereas 77.2% in *K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice did (Fig. 3b). This difference was highly significant ($p = 0.005$). We also investigated ER α status in the cervixes of two *CMVCreER/K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice that had CIN3 (see Table 1). We found that 79.0% of cervical stromal cells expressed ER α (Figs. 3b & c), which is comparable to *K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice (compare Fig. 3a, panel *iii* and Fig. 3c; $p = 0.22$). It is unclear why tamoxifen treatment was not efficient in activating cre activity in these two mice. Nonetheless, these results point further to the correlation between the retention of cervical neoplastic disease and ER α expression in the stroma. Female reproductive tracts were isolated from a subset of *CMVCreER/K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice a day after tamoxifen treatment for 3 or 5 days to confirm the absence of ER α deletion in cervical epithelia. While stromal ER α was deleted, expression of epithelial ER α was not affected (Fig. 3d), further supporting that absence of cervical diseases is due to loss of ER α in the stroma but not in the epithelium. Expression of progesterone receptor (PR) in the epithelium and stroma of female lower reproductive tracts is dependent upon ER α in the epithelium and stroma, respectively [15, 27]. We found that PR was expressed in cervical epithelial cells in *CMVCreER/K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice as well as *K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice (Fig. 3e). In contrast, PR expression was barely detectable in the ER α -deleted cervical stroma of the *CMVCreER/K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice, unlike ER α -intact stroma of *K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice. This result indicates that ER α is functional specifically in the epithelium, but not the stroma of *CMVCreER/K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice. Taken together, we conclude that stromal ER α is necessary for cervical carcinogenesis in HPV transgenic mouse model.

Deletion of stromal ER α abrogates cell proliferation in the cervical epithelia

We also investigated if estrogen-dependent epithelial cell proliferation in the cervixes of *CMVCreER/K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice was compromised. We found that proliferation indices of *K14E7/ERa^{fl/fl}* 8mE2 (-Tam), *K14E7/ERa^{fl/fl}* 8mE2 (+Tam), and *CMVCreER/K14E7/ERa^{fl/fl}* 8mE2 (-Tam) were similar in both basal (13.8~15.2%) and suprabasal layer (5.7~6.1%) of the cervical epithelia (Figs. 4a & b). These results demonstrate that tamoxifen or *CMVCreER* transgene, individually, had no effect on cervical epithelial cell proliferation, consistent with cervical disease phenotypes shown in Table 1. In contrast, proliferation indices of basal and suprabasal layer of the cervical epithelia of *CMVCreER/K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice were 1.6% and 0.1%, respectively (Figs. 4a & b). These proliferation indices were significantly lower than that observed in *K14E7/ERa^{fl/fl}* 8mE2 (+Tam) mice ($p = 0.03$) demonstrating that stromal ER α is necessary for proliferation of basal and suprabasal cells in the cervical epithelium.

Discussion

ER α plays a pivotal role in the development of various cancers including, but not limited to, breast cancers [20]. Estrogen cooperates with HPV oncogenes in a mouse model for HPV-associated cervical cancer [10-12, 34]; and ER α is required for this synergistic effect of estrogen and HPV oncogenes [13]. In this study, we investigated cell-type specific requirement of ER α in HPV-mediated cervical carcinogenesis, and learned that deletion of ER α in cervical stroma results in regression of CIN3 and dramatic reduction in cervical epithelial cell proliferation in *K14E7* transgenic mice (Table 1 & Figs. 3 & 4). Epithelial ER α was intact immediately after tamoxifen treatment and was functional as demonstrated by expression of PR in cervical epithelium of *CMVCreER/K14E7/ER α ^{fl/fl}* 8mE2 (+Tam) mice (Fig. 3e). These results indicate that epithelial ER α is not sufficient and stromal ER α is necessary for cervical carcinogenesis. These findings provide direct evidence that a paracrine mechanism mediated by stromal ER α is necessary for the maintenance of neoplastic state in the mouse cervix. It is, however, unclear if stromal ER α is required for continued growth of cervical cancer as well because we did not observe frank cancer in the control mice (*CMVCreER/K14E7/ER α ^{fl/fl}* 6mE2). Nonetheless, this is the first study to show the requirement of stromal ER α for estrogen-dependent cervical carcinogenesis *in vivo*. This finding is consistent with prior observations that ER α expression is retained in the stroma surrounding cervical cancer in women [35, 36]. Most breast cancer cells require ER α for continued growth and epithelial ER α is required for proliferation of mammary epithelial cells in mice [37]. Although a role of stromal ER α in the development of ER α -positive breast cancer has not been elucidated, ER α expressed in Tie2-positive stromal cells (e.g., endothelial cells) promotes growth of ER α -negative cancers by mediating adaptation of tumor angiogenesis [38]. ER α expressed in prostate stromal cells promotes expression of MMP2 via induction of TGF β 1, which enhances invasion of prostate cancer cells into Matrigel *in vitro* [39]. These results support the idea that stromal ER α may exert distinct functions depending on cancers.

A model for roles of ER α in cervical carcinogenesis

Although HPV oncogenes (*i.e.*, *E6* and *E7*) are necessary for continued growth of cervical cancer cells [40, 41], their ability to promote cell proliferation is largely restricted to the suprabasal layer of the murine cervical epithelium [12, 33]. However, this latter activity is severely compromised when expression of wt ER α is abolished in the whole reproductive tract [13]. ER α is known to induce proliferation in basal layer of the cervical epithelium but not in suprabasal layer [13]. We learned in this study that stromal ER α is necessary for the proliferation of both the basal and suprabasal cells within the cervical epithelium of *K14E7* mice (Fig. 4). These results are similar to prior findings showing a requirement of stromal ER α for physiologic proliferation of uterine columnar and vaginal squamous epithelial cells in response to estrogen [16, 22, 42]. Based on our and others' studies, we propose that stromal ER α provides a major mitogenic signal for basal cells in the cervical epithelium, which in turn supports suprabasal cell proliferation induced by HPV. HPV also inhibits apoptosis and induces chromosomal instability, which is known to promote cancers [4, 11, 43]. It has been proposed that epithelial ER α may also play a role in cervical carcinogenesis. Estrogen activates HPV promoter that drives *E6/E7* expression in the cervical epithelium of *HPV18URR-lacZ* transgenic mice [44]. Enhanced expression of *E6* and *E7* provides selective growth advantage to cells [45]. We predict that ER α is responsible for this regulation because ER α is not detectable in the cervix [13] and HPV genome contains putative estrogen responsive elements (EREs), ER α binding sites [46]. A negative role of epithelial ER α has been also demonstrated. ER α expressed in cervical cancer cells or dysplastic cells inhibits their ability to invade chick chorioallantoic membrane [47], which is consistent with the observation that ER α inhibits migration and invasion of breast cancer

cells [48-50]. It is plausible that epithelial ER α plays a positive role in early stages of carcinogenesis (*i.e.*, development of CIN) and a preventive role in later stages (*i.e.*, progression to invasive cancer and metastasis).

If this model were true, one would predict that deletion of ER α in cervical epithelia will enhance invasion of dysplastic cells, thereby increasing cancer burden in the context of our mouse model in which HPV oncogenes are under the control of K14 promoter unresponsive to estrogen [51]. Experiments to test this possibility were hampered by our inability to delete ER α in cervical epithelia (Online Resource 1 and Figs. 1 & 3). Use of *K14Cre* transgenic mice was also unsuccessful to induce efficient deletion of ER α in cervical epithelium even when ovaries were removed to block a potential selective pressure against ER α -deleted cells provided by estrogen (Online Resource 1). *K14Cre* transgenic mice have been used successfully to delete other floxed alleles (*e.g.*, *p53*, *pRb*) in cervical epithelium [31, 32] and the floxed ER α allele was readily deleted in cervical stroma and the whole uterus (Fig. 1). It is possible that *CMVCreER* is less active in cervical epithelia than in cervical stroma or whole uteri similar to mosaicism shown in *Chx10 BAC* transgenic mice [52, 53]. It is also possible that the absence of recombination in the cervical epithelia in *CMVCreER* and *K14Cre* mice reflects the fact that recombination efficiency varies depending on target alleles [53, 54].

Potential ER α target genes in stromal cells that are crucial for cervical carcinogenesis

It will be challenging to identify ER α target genes in cervical stromal cells that are necessary to support cervical carcinogenesis because (1) ER α is known to regulate (*i.e.*, activation and repression) thousands of genes and (2) it is unclear if the same genes are regulated by ER α when mice are treated with estrogen for hours compared to months (6 months in the case of our mouse model). However, the fact that paracrine factors induced by ER α likely contribute to the development of neoplastic states (Table 1 & Fig. 3) narrows down the list of candidate genes. Among them, insulin-like growth factor I (IGF-1), keratinocyte growth factor (KGF), and Wnt ligands are of particular interest. IGF-1 is a direct target of ER α and necessary for estrogen-induced cell proliferation in uterine epithelium [55, 56] and higher serum levels of IGF-1 are associated with increased risk for CIN [57]. KGF receptor is expressed in cervical cancer cell lines and cancer specimens [58]. In HPV16-immortalized human cervical epithelial cells, KGF promotes proliferation and anchorage-independent growth as well as secretion of urokinase-type plasminogen activator that is known associated with invasiveness of cancer cells [59, 60]. Inhibition of canonical wnt signaling abrogates estrogen-dependent epithelial cell proliferation in mouse uterus and wnt signaling is aberrantly activated in cervical cancer cell lines due to loss of *Skp1* [61-63].

In summary, we demonstrate that deletion of stromal ER α promotes regression of cervical neoplasia and abrogates epithelial cell proliferation in the cervix. These results provide an incentive for the pursuit of studies investigating the role of stromal ER α in other estrogen-dependent cancers and developing strategies to target stromal ER α to treat such cancers.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Denis Lee for technical assistance with immunohistochemistry. This study was supported by CA120847 grants from NIH to PFL and by the Texas Emerging Technology Fund, under Agreement 300-9-1958 to CNRCS. Funding support for KSK was provided by the Division of Intramural Research of NIEHS Z01ES70065.

References

1. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. *Best Pract Res Clin Obstet Gynaecol.* 2006; 20:207–225. [PubMed: 16359925]
2. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. *Nat Rev Cancer.* 2007; 7:11–22. [PubMed: 17186016]
3. Burd EM. Human papillomavirus and cervical cancer. *Clin Microbiol Rev.* 2003; 16:1–17. [PubMed: 12525422]
4. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. *Nat Rev Cancer.* 2002; 2:342–350. [PubMed: 12044010]
5. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. *Lancet.* 2007; 370:890–907. [PubMed: 17826171]
6. Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, Herrero R, Franceschi S. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. *Lancet.* 2002; 359:1085–1092. [PubMed: 11943255]
7. Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, Shah KV, Meijer CJ, Bosch FX. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. *Lancet.* 2002; 359:1093–1101. [PubMed: 11943256]
8. Chung SH, Franceschi S, Lambert PF. Estrogen and ERalpha: culprits in cervical cancer? *Trends Endocrinol Metab.* 2010; 21:504–511. [PubMed: 20456973]
9. Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. *Proc Natl Acad Sci U S A.* 2005; 102:2490–2495. [PubMed: 15699322]
10. Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ, Arbeit JM. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. *Cancer Res.* 2000; 60:1267–1275. [PubMed: 10728686]
11. Riley RR, Duensing S, Brake T, Munger K, Lambert PF, Arbeit JM. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. *Cancer Res.* 2003; 63:4862–4871. [PubMed: 12941807]
12. Shai A, Brake T, Somoza C, Lambert PF. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. *Cancer Res.* 2007; 67:1626–1635. [PubMed: 17308103]
13. Chung SH, Wiedmeyer K, Shai A, Korach KS, Lambert PF. Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. *Cancer Res.* 2008; 68:9928–9934. [PubMed: 19047174]
14. Chung SH, Lambert PF. Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. *Proc Natl Acad Sci U S A.* 2009; 106:19467–19472. [PubMed: 19901334]
15. Kurita T, Cooke PS, Cunha GR. Epithelial-stromal tissue interaction in paramesonephric (Mullerian) epithelial differentiation. *Dev Biol.* 2001; 240:194–211. [PubMed: 11784056]
16. Winuthayanon W, Hewitt SC, Orvis GD, Behringer RR, Korach KS. Uterine epithelial estrogen receptor alpha is dispensable for proliferation but essential for complete biological and biochemical responses. *Proc Natl Acad Sci U S A.* 2010; 107:19272–19277. [PubMed: 20974921]
17. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. *J Pathol.* 2003; 200:429–447. [PubMed: 12845611]
18. Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, Platzer P, Eng C. Breast-cancer stromal cells with TP53 mutations and nodal metastases. *N Engl J Med.* 2007; 357:2543–2551. [PubMed: 18094375]
19. Tanwar PS, Zhang L, Roberts DJ, Teixeira JM. Stromal deletion of the APC tumor suppressor in mice triggers development of endometrial cancer. *Cancer Res.* 2011; 71:1584–1596. [PubMed: 21363919]
20. Hewitt SC, Harrell JC, Korach KS. Lessons in estrogen biology from knockout and transgenic animals. *Annual review of physiology.* 2005; 67:285–308.

21. Deroo BJ, Korach KS. Estrogen receptors and human disease. *The J Clin Invest.* 2006; 116:561–570.
22. Cooke PS, Buchanan DL, Young P, Setiawan T, Brody J, Korach KS, Taylor J, Lubahn DB, Cunha GR. Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. *Proc Natl Acad Sci U S A.* 1997; 94:6535–6540. [PubMed: 9177253]
23. Mueller SO, Clark JA, Myers PH, Korach KS. Mammary gland development in adult mice requires epithelial and stromal estrogen receptor alpha. *Endocrinology.* 2002; 143:2357–2365. [PubMed: 12021201]
24. Herber R, Liem A, Pitot H, Lambert PF. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. *J Virol.* 1996; 70:1873–1881. [PubMed: 8627712]
25. Hewitt SC, Kissling GE, Fieselman KE, Jayes FL, Gerrish KE, Korach KS. Biological and biochemical consequences of global deletion of exon 3 from the ER alpha gene. *FASEB J.* 2010; 24:4660–4667. [PubMed: 20667977]
26. Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. *Dev Biol.* 2002; 244:305–318. [PubMed: 11944939]
27. Kurita T, Lee KJ, Cooke PS, Taylor JA, Lubahn DB, Cunha GR. Paracrine regulation of epithelial progesterone receptor by estradiol in the mouse female reproductive tract. *Biol Reprod.* 2000; 62:821–830. [PubMed: 10727249]
28. Balsitis S, Dick F, Lee D, Farrell L, Hyde RK, Griep AE, Dyson N, Lambert PF. Examination of the pRb-dependent and pRb-independent functions of E7 in vivo. *J Virol.* 2005; 79:11392–11402. [PubMed: 16103190]
29. Seibler J, Zevnik B, Kuter-Luks B, Andreas S, Kern H, Hennek T, Rode A, Heimann C, Faust N, Kauselmann G, et al. Rapid generation of inducible mouse mutants. *Nucleic Acids Res.* 2003; 31:e12. [PubMed: 12582257]
30. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. *Proc Natl Acad Sci U S A.* 1993; 90:11162–11166. [PubMed: 8248223]
31. Balsitis S, Dick F, Dyson N, Lambert PF. Critical roles for non-pRb targets of human papillomavirus type 16 E7 in cervical carcinogenesis. *Cancer Res.* 2006; 66:9393–9400. [PubMed: 17018593]
32. Shai A, Pitot HC, Lambert PF. p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. *Cancer Res.* 2008; 68:2622–2631. [PubMed: 18413729]
33. Shin MK, Balsitis S, Brake T, Lambert PF. Human papillomavirus E7 oncoprotein overrides the tumor suppressor activity of p21Cip1 in cervical carcinogenesis. *Cancer Res.* 2009; 69:5656–5663. [PubMed: 19584294]
34. Maufort JP, Shai A, Pitot HC, Lambert PF. A role for HPV16 E5 in cervical carcinogenesis. *Cancer Res.* 2010; 70:2924–2931. [PubMed: 20332225]
35. Kwasniewska A, Postawski K, Gozdzicka-Jozefiak A, Kwasniewski W, Grywalska E, Zdunek M, Korobowicz E. Estrogen and progesterone receptor expression in HPV-positive and HPV-negative cervical carcinomas. *Oncol Rep.* 2011; 26:153–160. [PubMed: 21491087]
36. Mosny DS, Herholz J, Degen W, Bender HG. Immunohistochemical investigations of steroid receptors in normal and neoplastic squamous epithelium of the uterine cervix. *Gynecol Oncol.* 1989; 35:373–377. [PubMed: 2599474]
37. Feng Y, Manka D, Wagner KU, Khan SA. Estrogen receptor-alpha expression in the mammary epithelium is required for ductal and alveolar morphogenesis in mice. *Proc Natl Acad Sci U S A.* 2007; 104:14718–14723. [PubMed: 17785410]
38. Pequeux C, Raymond-Letron I, Blacher S, Boudou F, Adlanmerini M, Fouque MJ, Rochaix P, Noel A, Foidart JM, Krust A, et al. Stromal estrogen receptor-alpha promotes tumor growth by normalizing an increased angiogenesis. *Cancer Res.* 2012; 72:3010–3019. [PubMed: 22523036]
39. Yu L, Wang CY, Shi J, Miao L, Du X, Mayer D, Zhang J. Estrogens promote invasion of prostate cancer cells in a paracrine manner through up-regulation of matrix metalloproteinase 2 in prostatic stromal cells. *Endocrinology.* 2011; 152:773–781. [PubMed: 21248144]

40. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. *Clin Sci (Lond)*. 2006; 110:525–541. [PubMed: 16597322]
41. Nishimura A, Nakahara T, Ueno T, Sasaki K, Yoshida S, Kyo S, Howley PM, Sakai H. Requirement of E7 oncoprotein for viability of HeLa cells. *Microbes Infect*. 2006; 8:984–993. [PubMed: 16500131]
42. Buchanan DL, Kurita T, Taylor JA, Lubahn DB, Cunha GR, Cooke PS. Role of stromal and epithelial estrogen receptors in vaginal epithelial proliferation, stratification, and cornification. *Endocrinology*. 1998; 139:4345–4352. [PubMed: 9751518]
43. Spardy N, Duensing A, Charles D, Haines N, Nakahara T, Lambert PF, Duensing S. The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells. *J Virol*. 2007; 81:13265–13270. [PubMed: 17898070]
44. Morales-Peza N, Auewarakul P, Juarez V, Garcia-Carranca A, Cid-Arregui A. In vivo tissue-specific regulation of the human papillomavirus type 18 early promoter by estrogen, progesterone, and their antagonists. *Virology*. 2002; 294:135–140. [PubMed: 11886272]
45. Jeon S, Allen-Hoffmann BL, Lambert PF. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. *J Virol*. 1995; 69:2989–2997. [PubMed: 7707525]
46. Mitrani-Rosenbaum S, Tsvieli R, Tur-Kaspa R. Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. *J Gen Virol*. 1989; 70(Pt 8):2227–2232. [PubMed: 2549190]
47. Zhai Y, Bommer GT, Feng Y, Wiese AB, Fearon ER, Cho KR. Loss of estrogen receptor 1 enhances cervical cancer invasion. *Am J Pathol*. 2010; 177:884–895. [PubMed: 20581058]
48. Goto N, Hiyoshi H, Ito I, Tsuchiya M, Nakajima Y, Yanagisawa J. Estrogen and antiestrogens alter breast cancer invasiveness by modulating the transforming growth factor-beta signaling pathway. *Cancer Sci*. 2011; 102:1501–1508. [PubMed: 21564419]
49. Platet N, Cunat S, Chalbos D, Rochefort H, Garcia M. Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. *Mol Endocrinol*. 2000; 14:999–1009. [PubMed: 10894150]
50. Rochefort H, Chalbos D, Cunat S, Lucas A, Platet N, Garcia M. Estrogen regulated proteases and antiproteases in ovarian and breast cancer cells. *J Steroid Biochem Mol Biol*. 2001; 76:119–124. [PubMed: 11384869]
51. Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. *Proc Natl Acad Sci U S A*. 1996; 93:2930–2935. [PubMed: 8610145]
52. Rowan S, Cepko CL. Genetic analysis of the homeodomain transcription factor Chx10 in the retina using a novel multifunctional BAC transgenic mouse reporter. *Dev Biol*. 2004; 271:388–402. [PubMed: 15223342]
53. Niculescu C, Ganguli-Indra G, Pfister V, Dupe V, Messaddeq N, De Arcangelis A, Georges-Labouesse E. Conditional ablation of integrin alpha-6 in mouse epidermis leads to skin fragility and inflammation. *Eur J Cell Biol*. 2011; 90:270–277. [PubMed: 20965608]
54. Castilho RM, Squarize CH, Patel V, Millar SE, Zheng Y, Molinolo A, Gutkind JS. Requirement of Rac1 distinguishes follicular from interfollicular epithelial stem cells. *Oncogene*. 2007; 26:5078–5085. [PubMed: 17334398]
55. Hewitt SC, Li Y, Li L, Korach KS. Estrogen-mediated regulation of Igf1 transcription and uterine growth involves direct binding of estrogen receptor alpha to estrogen-responsive elements. *J Biol Chem*. 2010; 285:2676–2685. [PubMed: 19920132]
56. Zhu L, Pollard JW. Estradiol-17beta regulates mouse uterine epithelial cell proliferation through insulin-like growth factor 1 signaling. *Proc Natl Acad Sci U S A*. 2007; 104:15847–15851. [PubMed: 17895382]
57. Wu X, Tortolero-Luna G, Zhao H, Phatak D, Spitz MR, Follen M. Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. *Clin Cancer Res*. 2003; 9:3356–3361. [PubMed: 12960122]

58. Kurban G, Ishiwata T, Kudo M, Yokoyama M, Sugisaki Y, Naito Z. Expression of keratinocyte growth factor receptor (KGFR/FGFR2 IIIb) in human uterine cervical cancer. *Oncol Rep.* 2004; 11:987–991. [PubMed: 15069536]
59. Zheng J, Saksela O, Matikainen S, Vaheri A. Keratinocyte growth factor is a bifunctional regulator of HPV16 DNA-immortalized cervical epithelial cells. *J Cell Biol.* 1995; 129:843–851. [PubMed: 7730415]
60. Zheng J, Siren V, Vaheri A. Keratinocyte growth factor enhances urokinase-type plasminogen activator activity in HPV16 DNA-immortalized human uterine exocervical epithelial cells. *Eur J Cell Biol.* 1996; 69:128–134. [PubMed: 8907612]
61. Jacob LS, Wu X, Dodge ME, Fan CW, Kulak O, Chen B, Tang W, Wang B, Amatruda JF, Lum L. Genome-wide RNAi screen reveals disease-associated genes that are common to Hedgehog and Wnt signaling. *Sci Signal.* 2011; 4:ra4. [PubMed: 21266715]
62. Hou X, Tan Y, Li M, Dey SK, Das SK. Canonical Wnt signaling is critical to estrogen-mediated uterine growth. *Mol Endocrinol.* 2004; 18:3035–3049. [PubMed: 15358837]
63. Sonderegger S, Pollheimer J, Knofler M. Wnt signalling in implantation, decidualisation and placental differentiation--review. *Placenta.* 2010; 31:839–847. [PubMed: 20716463]

Fig. 1. Tamoxifen induces efficient deletion of ER α only in cervical stroma of *CMVCreER/ER α ^{f/f}* mice. **a** Tamoxifen treatment induces atrophic female reproductive tracts in *CMVCreER/ER α ^{f/f}* mice. *ER α ^{f/f}* (*CMVCreER*⁻, left) and *CMVCreER/ER α ^{f/f}* (*CMVCreER*⁺, right) mice were i.p. injected with tamoxifen (4 mg/day for 5 days). The female reproductive tracts were harvested two weeks after the first dose. Black and red arrowheads indicate ovaries and hemorrhagic cysts, respectively. u, uterus; c, cervix; v, vagina. Scale bar, 5 mm. **b** ER α expression is retained in the cervical epithelium of *CMVCreER/ER α ^{f/f}* mice treated with tamoxifen. Mice were treated as in (a) and paraffin sections were stained for ER α (green). DAPI-stained nuclei are pseudocolored red. Note that ER α is readily detected in cervical epithelium (e) but not in cervical stroma (s) (*upper panel*) and both compartments of the uterus (*bottom panel*) in *CMVCreER/ER α ^{f/f}* mice. Dotted lines indicate basement membrane separating epithelium from stroma. Scale bar, 50 μ m.

Fig. 2. Cervical disease is absent in *CMVCreER/K14E7/ERα^{fl/fl}* mice treated with tamoxifen. **a** Treatment regimen is depicted. E2 and Tam indicate estrogen and tamoxifen, respectively. **b** Shown are high-magnification images of representative H&E-stained endocervical sections from indicated groups of mice. Arrows point to atypia manifested as dark and enlarged nuclei. Note that cervical intraepithelial neoplasia (CIN) is evident in *K14E7/ERα^{fl/fl}* 8mE2(-Tam), *CMVCreER/K14E7/ERα^{fl/fl}* 8mE2 (-Tam), and *K14E7/ERα^{fl/fl}* 8mE2 (+Tam) mice (panels i-iii) but absent in *CMVCreER/K14E7/ERα^{fl/fl}* 8mE2 (+Tam) mice (panel iv). Scale bar, 20 μm.

Fig. 3.

Cervical disease states correlates with the ERα status in the cervical stroma. **a** ERα expression is ablated in the cervical stroma of *CMVCreER/K14E7/ERα^{fl/fl}* 8mE2 (+Tam) mice without cervical disease. Paraffin sections of female reproductive tracts from indicated groups of mice were stained for ERα (green). All diseased mice expressed ERα in both epithelium and stroma of the cervix (*panels i-iii*), yet ERα was barely detectable in the cervical stroma of disease-free *CMVCreER/K14E7/ERα^{fl/fl}* 8mE2 (+Tam) mice (*panel iv*). DAPI-stained nuclei are pseudocolored red. Scale bar, 20 μm. **b** Results shown in (**a**) and (**c**) were quantified for number of ERα⁺ cells. At least 1000 cervical stromal cells in 4 random fields of each female reproductive tract were analyzed. Data are shown as mean ± SEM. *P* value for two-sided Wilcoxon rank sum test is shown. **c** ERα expression is retained in cervical stroma of *CMVCreER/K14E7/ERα^{fl/fl}* 8mE2 (+Tam) mice with CIN. Paraffin sections from female reproductive tracts of the two mice that had cervical disease in the *CMVCreER/K14E7/ERα^{fl/fl}* 8mE2 (+Tam) group were stained for ERα (green). DAPI-stained nuclei are pseudocolored red. Scale bar, 20 μm. **d** Epithelial ERα is not deleted shortly after tamoxifen treatment. Mice were treated with E2 for 6 months, treated with tamoxifen (4mg) for 3 days (*top panel*) or 5 days (*bottom panel*), and sacrificed a day later. Paraffin sections were subjected to ERα IHC (green). DAPI-stained nuclei are pseudocolored red. Scale bar, 50 μm. **e** PR is expressed in the cervical epithelium of *CMVCreER/K14E7/ERα^{fl/fl}* 8mE2 (+Tam) mice. Cervical tissues from indicated study groups were subjected to PR IHC (brown nuclei). Nuclei were counterstained with hematoxylin. Representative images from three mice in each group are shown. The black lines point to basement membrane. Scale bar, 50 μm.

Fig. 4.

Cervical epithelial cell proliferation is significantly reduced when ER α expression is ablated in the stromal cells. **a** BrdU incorporation is reduced in the cervical epithelia of *CMVCreER/K14E7/ER α ^{f/f}* 8mE2 (+Tam) mice. Paraffin sections from indicated study groups were stained for BrdU to measure cell proliferation (brown nuclei). Nuclei were counterstained with hematoxylin. Representative images from three mice for each group are shown. Scale bar, 20 μ m. **b** BrdU⁺ cells shown in (a) were quantified. Data are shown as mean $\pm$ SEM (n = 3). *P* values for two-sided Wilcoxon rank sum test are shown.

Table 1

State of Lower Reproductive Tract Disease^a

Group name (Genotype & treatment)	ERα status		Group size (n)	No disease		Dysplasia only			Cancer & dysplasia	
	Stroma	Epithelia		Cervix (Vagina)		CIN1 (VIN1)	CIN2 (VIN2)	CIN3 (VIN3)	Cervix (Vagina)	
<i>K14E7/ERα^{fl}</i> 6mE2	+	+	14	0 (0)		0 (0)	0 (5)	14 (9)		0 (0)
<i>CMVCreER/K14E7/ERα^{fl}</i> 6mE2	+	+	14	2 (2)		0 (0)	1 (3)	11 (9)		0 (0)
<i>K14E7/ERα^{fl}</i> 8mE2 (+Tam)	+	+	18	4 (3)		0 (0)	0 (2)	13 (12)		1 (0)
<i>K14E7/ERα^{fl}</i> 8mE2 (-Tam)	+	+	15	0 (0)		0 (0)	0 (1)	13 (13)		2 (0)
<i>CMVCreER/K14E7/ERα^{fl}</i> 8mE2 (+Tam)	-	+	18	16 (16)		0 (0)	0 (1)	2 (1)		0 (0)
<i>CMVCreER/K14E7/ERα^{fl}</i> 8mE2 (-Tam)	+	+	4	0 (0)		0 (0)	0 (1)	3 (3)		1 (0)

Note: for Wilcoxon rank sum test (see text), each lesion was given the following arbitrary score; no disease = 1; CIN1 (VIN1) = 2; CIN2 (VIN2) = 3; CIN3 (VIN3) = 4; cancer = 5.

^aMice were scored histopathologically for the worst disease present in the cervix or, in parentheses, the vagina. CIN, cervical intraepithelial neoplasia; VIN, vaginal intraepithelial neoplasia.